Get your beauty sleep
PlexusDx requires a telehealth consultation with a licensed healthcare provider who reviews your medical history, current medications, and vital signs before treatment begins
To meet the diagnostic criteria for dEDS, a person must meet: Major criterion 1 AND major criterion 2 AND at least one other major criterion OR Major criterion 1 AND major criterion 2 AND at least three minor criteria Major Criteria Extreme skin fragility with congenital or postnatal skin tears Characteristic craniofacial features, which are evident at birth or early infancy or evolve later in childhood Redundant, almost lax skin, with excessive skin folds at the wrists and ankles Increased palmar wrinkling Severe bruisability with a risk of subcutaneous hematomas and hemorrhage Umbilical hernia Postnatal growth retardation Short limbs, hands, and feet Perinatal complications due to connective tissue fragility Minor Criteria Soft and doughy skin texture Skin hyperextensibility Atrophic scars Generalized joint hypermobility Complications of visceral fragility (e.g., bladder rupture, diaphragmatic rupture, rectal prolapse) Delayed motor development Osteopenia Hirsutism Tooth abnormalities Refractive errors (myopia, astigmatism) Strabismus Kyphoscoliotic EDS (kEDS) If a person meets the diagnostic criteria for kEDS, genetic testing should be done to confirm the diagnosis
As interest in peptide therapy continues growing, many patients are asking an important question: What are the side effects of BPC-157 peptide therapy and how can they be prevented? At GoalBMI Wellness, patients exploring wellness-focused peptide therapy often want to better understand both the potential benefits and the possible risks before starting treatment
This product is intended solely for research purposes and is not for human consumption
Participants receiving Retatrutide at the 12 mg dose achieved average weight loss of 24.2% over 48 weeks
/assets/images/provider/photos/2636389.jpg)
